USPTO published patent application US20260091094A1 (Kind A1) on April 2, 2026, disclosing neurotoxin compositions for treating gastroparesis. The application (No. 19413766) was filed December 9, 2025, by inventors Gregory F. Brooks and Eric Carter. CPC classifications indicate therapeutic protein preparations (A61K 38/4893), pharmaceutical compositions (A61K 9/0019), and gastroparesis treatments (A61P 1/14).\n\nThis is a routine patent publication establishing priority date and placing the invention in the public record as prior art. Pharmaceutical companies and healthcare researchers developing gastroparesis treatments should conduct freedom-to-operate analyses. Entities investing in this therapeutic area should review the claims to assess potential IP conflicts with existing or future patent portfolios.